Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $5.6052W HIGH $11.00
Volume
214.40 K
Value Traded
487.39 K
Short % Float
13.16%
-7.34%Week
-21.52%1 Month
-27.91%3 Month
+14.05%6 Month
-92.97%5 Year
-98.5%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
206.34 M
EPS (TTM)
-5.02
P/E Ratio
-
Ent. Value
111.59 M
Total Shares
30.26 M
Float Shares
13.70 M
Insiders
54.73%
Institutions
28.85%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
RNAC Catalyst Timeline
Dated clinical, regulatory and corporate events for Cartesian Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Cartesian Therapeutics, Inc.
343Total events
11Upcoming
75Tier-1 (high impact)
2016 to 2028Coverage
Upcoming catalysts 2
Event history 50
▲Safety Data UpdateDescartes-08Clinical Data
No new safety signals reported with Descartes-08 retreatment through Month 12
generalized myasthenia gravissource ↗
▲Oral PresentationDescartes-08Presentation
Descartes-08 retreatment data presented at 2026 AANEM Annual Meeting
generalized myasthenia gravissource ↗
▲Additional DataDescartes-08Clinical Data
Additional positive 12-month retreatment data for Descartes-08 in MG presented at AANEM
generalized myasthenia gravissource ↗
◆Trial InitiationDescartes-08Trial
Phase 1 dose-escalation study of Descartes-08 mRNA via WestGene tLNPs in MG expected to initiate
generalized myasthenia gravissource ↗
▲Partnership / LicenseCorporate
Strategic licensing agreement with WestGene Biopharma for in vivo CAR-T platform
▲Debt Royalty FinancingCorporate
Secured up to $150 million non-dilutive credit facility from K2 HealthVentures, initial $50 million tranche funded
◆Oral PresentationPresentation
Cartesian Therapeutics to participate in H.C. Wainwright BioConnect Investor Conference fireside chat
◆Enrollment UpdateDescartes-08Trial
Multiple patients enrolled in Phase 1/2 HELIOS pediatric trial of Descartes-08 in juvenile dermatomyositis
juvenile dermatomyositissource ↗
▲Trial InitiationDescartes-08Trial
Phase 2 TRITON trial of Descartes-08 in myositis initiated
dermatomyositis and antisynthetase syndromesource ↗
▼Program DiscontinuationDescartes-08Corporate
Decision to no longer pursue development of Descartes-08 in systemic lupus erythematosus
systemic lupus erythematosussource ↗
◆Enrollment UpdateDescartes-08Trial
Phase 1/2 HELIOS pediatric trial of Descartes-08 in juvenile dermatomyositis actively enrolling
juvenile dermatomyositissource ↗
▲Enrollment UpdateDescartes-08Trial
Enrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis
myasthenia gravissource ↗
▲IND ClearanceDescartes-08IND
IND application for Descartes-08 in myositis accepted by FDA
myositissource ↗
▲Trial InitiationDescartes-08Trial
Phase 1/2 pediatric trial of Descartes-08 in juvenile dermatomyositis initiated
juvenile dermatomyositissource ↗
▲PublicationDescartes-08Presentation
Publication of Phase 2b trial results in Nature Medicine
myasthenia gravissource ↗
▲IND ClearanceDescartes-08IND
FDA accepted IND for Phase 2 TRITON trial in myositis
myositis (dermatomyositis and antisynthetase syndrome)source ↗
◆Topline ReadoutDescartes-08Clinical Data
Preliminary data from Phase 2 trial of Descartes-08 in SLE expected by end of year
systemic lupus erythematosussource ↗
◆Trial InitiationDescartes-08Trial
Initiation of Phase 2 pediatric basket trial of Descartes-08 in select autoimmune indications expected by end of year
select autoimmune indicationssource ↗
▲Topline ReadoutDescartes-08Clinical Data
Initial data from Phase 2 open-label trial of Descartes-08 in SLE: 100% LLDAS response rate and DORIS remission in 2 of 3 patients at Month 3
systemic lupus erythematosus (SLE)source ↗
▼Program DiscontinuationDescartes-08Corporate
Pause further development of Descartes-08 in SLE, including enrollment in Phase 2 trial
systemic lupus erythematosus (SLE)source ↗
▼Program DiscontinuationDescartes-08Corporate
Pause development of Descartes-15 in multiple myeloma
multiple myelomasource ↗
▲Safety Data UpdateDescartes-08Clinical Data
Preliminary safety data from Phase 1 dose escalation trial: no significant AEs or DLTs in 3 patients
multiple myelomasource ↗
◆Enrollment UpdateDescartes-08Trial
Enrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis
myasthenia gravissource ↗
◆Topline ReadoutDescartes-08Clinical Data
Preliminary data from Phase 2 trial of Descartes-08 in SLE expected
systemic lupus erythematosussource ↗
▲Trial InitiationDescartes-08Trial
Initiation of Phase 2 pediatric basket trial of Descartes-08 in select autoimmune indications expected
juvenile autoimmune diseasessource ↗
◆Oral PresentationPresentation
Participation in Stifel 2025 Immunology and Inflammation Virtual Conference
◆Oral PresentationPresentation
Participation in Morgan Stanley 23rd Annual Global Healthcare Conference
◆Oral PresentationPresentation
Participation in H.C. Wainwright 25th Annual Global Investment Conference
◆Topline ReadoutDescartes-08Clinical Data
Preliminary data from Phase 2 open-label trial of Descartes-08 in SLE expected in 2H25
systemic lupus erythematosussource ↗
◆Trial InitiationDescartes-08Trial
Phase 2 pediatric basket trial of Descartes-08 expected to initiate in 2H25
juvenile autoimmune indicationssource ↗
▲First Patient DosedDescartes-08Trial
First participant enrolled in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis
myasthenia gravissource ↗
◆Oral PresentationPresentation
Cartesian Therapeutics to participate in H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ
◆Oral PresentationDescartes-08Presentation
Encore presentation at 15th International Conference on Myasthenia Gravis and Related Disorders
myasthenia gravissource ↗
Past FDA Catalysts and PDUFA Decisions
How RNAC actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C49 / 100
Pipeline Score
$129M
Pipeline Value
Overvalued
Valuation Signal
1
Drugs Scored
0.6x
rNPV / MCap
Top 20%
Micro Cap(rank 132 of 658)
Percentile Rank
Cartesian Therapeutics, Inc. carries a moderate pipeline score (49/100), with $876M risk-adjusted pipeline value, led by Descartes-08 in Multiple Myeloma (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Descartes-08 Monoclonal antibodyNCT06799247 | Myasthaenia Gravis | Phase 3 | ACTIVE NOT_RECRUITING | 128 | Sep 30, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every RNAC program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Descartes-08 RMATOrphanRare Pediatric | myasthenia gravis | Phase 2b | 2026-09-29 | mean MG ADL reduction: 6.6; median interval between treatments: 16.6; mean MGC reduction: 15Read More | Cartesian Therapeutics Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia GravisRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Hoge Elizabeth10% Owner | Option | 758,001 5,313,261 held | $0.00 | 04/02/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in RNAC
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Ikarian Capital, LLC | 0 % | 216.00 K | 20.81 K |
RNAC Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How RNAC ranks across every disease it competes in
Competitive Position is a premium feature
See how RNAC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialRNAC News
RNACCartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics has announced the granting of inducement awards to four new employees, totaling 121,900 stock options. These options have an exercise price of $7.22 and will vest over a period of four years. This move is part of the company's strategy to attract talent as it advances its cell therapy initiatives for autoimmune diseases.
Read more →RNACCartesian Therapeutics Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia Gravis
Cartesian Therapeutics announced positive retreatment data for Descartes-08 in myasthenia gravis patients, showing a mean MG-ADL score reduction of 6.6 points at Month 12. The median interval between treatments was 16.6 months, with no new safety concerns reported. Topline data from the Phase 3 AURORA trial is expected in Q1 2027.
Read more →RNACCartesian Therapeutics to Participate in Upcoming Investor Conferences
Cartesian Therapeutics, a late clinical-stage biotechnology firm, announced its participation in several investor conferences in September 2026. The events include a fireside chat at the Cantor Global Healthcare Conference and meetings at the Morgan Stanley Healthcare Conference. The company is known for its pioneering work in cell therapy for autoimmune diseases.
Read more →RNACCartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Cartesian Therapeutics reported its Q2 2026 financial results, highlighting advancements in the Phase 3 AURORA trial for Descartes-08 in myasthenia gravis, with data expected in Q1 2027. The company also announced a partnership with WestGene to develop an in vivo CAR-T platform. Financially, Cartesian has secured up to $150 million in non-dilutive financing, ensuring operational support into 2028.
Read more →RNAC▼ -9.6%on this news
Cartesian Therapeutics Announces New Employment Inducement Grant
Cartesian Therapeutics has announced an employment inducement grant for a new employee, offering an option to purchase 6,100 shares at $5.86. This option, part of the company's incentive plan, vests over four years and has a ten-year term. The grant aims to attract talent as the company advances its clinical-stage cell therapies for autoimmune diseases.
Read more →RNAC▲ +16.9%on this news· ran to +62% by day 3shared move
Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases
Cartesian Therapeutics has entered a strategic licensing agreement with WestGene Biopharma to enhance the development of in vivo CAR-T therapies targeting autoimmune diseases. This collaboration aims to leverage WestGene's lipid nanoparticle platform and Cartesian's mRNA payload, with clinical trials expected to start in the second half of 2026. The partnership is anticipated to accelerate the path to clinical proof-of-concept data.
Read more →RNACCartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027
Cartesian Therapeutics has secured an agreement with K2 HealthVentures for up to $150 million in non-dilutive financing, with an initial $50 million tranche extending its cash runway into 2028. This funding will support multiple clinical programs, including the Phase 3 AURORA trial for Descartes-08 in myasthenia gravis, expected to yield topline data in the first quarter of 2027. The company is also advancing trials in myositis and juvenile dermatomyositis, reflecting ongoing commitment to its clinical pipeline. However, the announcement noted the planned departure of the CMO, which could affect company operations.
Read more →RNACCartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
Cartesian Therapeutics, a late clinical-stage biotechnology company, will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026. The event will feature a fireside chat with management, which will be accessible via a live webcast. The company is focused on developing cell therapies for autoimmune diseases, with its lead asset currently in various phases of clinical development.
Read more →RNACCartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Cartesian Therapeutics reported its first quarter 2026 financial results, highlighting ongoing progress in multiple clinical trials for its lead candidate, Descartes-08. The company remains focused on its Phase 3 AURORA trial for myasthenia gravis, while also initiating a Phase 2 trial for myositis. Financially, Cartesian holds $120.4 million in cash, expected to support operations into mid-2027.
Read more →RNAC▲ +31.7%on this news
Cartesian Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update
Cartesian Therapeutics reported its financial results for 2025, highlighting progress in the Phase 3 AURORA trial for Descartes-08 in myasthenia gravis. The company has sufficient cash reserves to support operations through mid-2027 and plans to initiate additional trials in myositis and juvenile dermatomyositis in 2026. CEO Carsten Brunn emphasized the potential of Descartes-08 to redefine treatment standards.
Read more →RNACCartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook
Cartesian Therapeutics has made significant strides in its clinical pipeline, particularly with Descartes-08 for myasthenia gravis and myositis. The ongoing Phase 3 AURORA trial is progressing well, and the FDA has accepted the IND application for a pivotal trial in myositis. The company is also initiating a Phase 1/2 trial for juvenile dermatomyositis, showcasing its commitment to advancing treatments for autoimmune diseases.
Read more →RNACCartesian Therapeutics Announces the Appointment of Adrian Bot to Board of Directors
Cartesian Therapeutics has appointed Dr. Adrian Bot to its Board of Directors, bringing over 30 years of experience in biopharma, particularly in cell therapy and immune engineering. Dr. Bot, known for his work in CAR T cell therapies, will contribute to the Science and Technology Committee as the company focuses on advancing its clinical pipeline. Cartesian is currently developing its lead asset, Descartes-08, which is in Phase 3 trials for generalized myasthenia gravis and has plans for trials in myositis.
Read more →About Cartesian Therapeutics, Inc.
Headquarters7495 NEW HORIZON WAY, FREDERICK, MD, 21703
BIOPHARMAWATCH ELITE PLUS
Trade the next RNAC catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime